Tag: biocon
Browse our exclusive articles!
Biosimilar ramp-up to drive growth for Biocon in FY27
New biosimilar launches and scaling up of recently launched products are expected to drive growth for Biocon in FY27, as the company pivots from...
Biocon shares decline after USFDA issues Form 483 with five observations for Bengaluru unit
Biocon Ltd. shares declined in early trade on Thursday, April 30, after the company said the US drug regulator has issued a Form 483...
Biocon gains after Health Canada nod for cancer, osteoporosis drugs
Shares of Biocon Ltd. rose on Tuesday, April 21, after the company received approval from Health Canada for two denosumab biosimilars, Bosaya and Vevzuo,...
Overseas acquisitions: Indian drugmakers shop for deals abroad as they move away from generics
"In terms of outbound deals in pharma, with the top 10-15 players, certainly we are seeing an increase in appetite,” said Subhakanta Bal, managing...
Biocon launches bone therapy biosimilars Bosaya, Aukelso in US market
Biocon Limited on Tuesday, April 7, announced the commercial launch of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States.As per the exchange filling,...
